ArticleClinical and experimental medicine2007
ApoE epsilon2/epsilon3/epsilon4 polymorphism, ApoC-III/ApoE ratio and metabolic syndrome.
Article in Clinical and experimental medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- Association between APOE genotypes and metabolic syndrome in a middle aged and elderly Urban South Indian population.Metabolism open · 2024Article
- Sex-specific differences in the association between APOE genotype and metabolic syndrome among middle-aged and older rural Indians.Metabolism open · 2024Article
- Effect of high-fat diet and empagliflozin on cardiac proteins in mice.Nutrition & metabolism · 2022Article
- β-Cell Dysfunction, Hepatic Lipid Metabolism, and Cardiovascular Health in Type 2 Diabetes: New Directions of Research and Novel Therapeutic Strategies.Biomedicines · 2021Review
- Understanding the Exchange of Systemic HDL Particles Into the Brain and Vascular Cells Has Diagnostic and Therapeutic Implications for Neurodegenerative Diseases.Frontiers in physiology · 2021Review
- Beyond the CNS: The many peripheral roles of APOE.Neurobiology of disease · 2020Review
- Inflammaging in Endemic Areas for Infectious Diseases.Frontiers in immunology · 2020Review
- Apolipoprotein E Gene Polymorphism and Subclinical Carotid Atherosclerosis: The Northern Manhattan Study.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2018Article
- Prospective associations of exercise and depressive symptoms in older adults: the role of apolipoprotein E4.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2017Article
- Cardiometabolic risk factors predict cerebrovascular health in older adults: results from the Brain in Motion study.Physiological reports · 2016Article
- Lack of association of apolipoprotein E (Apo E) polymorphism with the prevalence of metabolic syndrome: the National Heart, Lung and Blood Institute Family Heart Study.Diabetes/metabolism research and reviews · 2015Article
- Diversity of apolipoprotein E genetic polymorphism significance on cardiovascular risk is determined by the presence of metabolic syndrome among hypertensive patients.Lipids in health and disease · 2014Article
- Different associations of apoE gene polymorphism with metabolic syndrome in the Vojvodina Province (Serbia).Molecular biology reports · 2014Article
- Does low birth weight affect the presence of cardiometabolic risk factors in overweight and obese children?European journal of pediatrics · 2013Article
- Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor.Diabetes · 2011Article
- Genetic variants in lipid metabolism are independently associated with multiple features of the metabolic syndrome.Lipids in health and disease · 2011Article
- Apolipoprotein E gene polymorphism and polycystic ovary syndrome patients in Western Anatolia, Turkey.Journal of assisted reproduction and genetics · 2009Article
- The Different Faces of the Pancreatic Islet.Advances in experimental medicine and biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triglyceride-rich lipoproteins contain both apolipoproteins E (ApoE) and C-III (ApoC-III), which show opposite functional properties. The relationships between the ApoE (epsilon2/epsilon3/epsilon4) gene polymorphism and ApoC-III/ApoE ratio has never been investigated. A large population (n=552) of cardiovascular patients, without diabetes and/or lipid-lowering therapy, with or without metabolic syndrome (MetSyn), was genotyped for epsilon2/epsilon3/epsilon4 polymorphism and their ApoCIII/ApoE ratio was evaluated. A second group of patients (n=76) with peripheral artery disease was also genotyped and their ApoC-III/ApoE ratios were measured in HDL and non-HDL fractions. Subjects with E2 had higher and E4 carriers lower TG,ApoE and ApoC-III levels, respectively. The ApoCIII/ ApoE ratio showed an opposite trend, gradually increasing from E2/E2 to E4/E4 subjects. MetSyn patients also had an elevated ApoC-III/ApoE ratio and E4 carriers were more frequent in MetSyn patients (OR 2.08 with a 95%CI 1.22-3.5). The distribution of ApoC-III/ApoE ratio was confirmed also in the second group, with lower values in E2/E3 and higher in E3/E4 subjects. Similar results were obtained for the concentrations measured in non-HDL fractions, but not in the HDL fractions. ApoE epsilon2/epsilon3/epsilon4 gene polymorphism is a determinant of the relative proportion of apolipoprotein C-III to E. Carriers of the unfavourable E4 allele present the highest ApoCIII/ApoE ratio and are twofold more frequent among individuals affected by MetSyn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.